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Background: The purpose of this study was to explore whether newer galenic formulations 
with lower treatment burdens are associated with better patient compliance and persistence 
compared with older more burdensome modalities.
Methods: Data from the IMS Disease Analyzer database were analyzed retrospectively for 
two pairs of analogs (alendronate sodium once daily vs once weekly and immediate-release vs 
extended-release methylphenidate) and one pair of drugs with similar indications but important 
differences in convenience and dosing instructions (desferrioxamine vs deferasirox). Compliance 
was calculated as the sum of prescription durations for all prescriptions for each patient over 
1 year. Persistence was calculated as the time between first and last prescriptions over 2 years 
(1 year for deferasirox and desferrioxamine). Data from Germany and the UK were available 
and used for analysis.
Results: Incremental improvements in compliance were +30% in the UK and +26% in   Germany 
for alendronate once weekly vs once daily, +14% in the UK and +19% in   Germany for extended-
release vs immediate-release methylphenidate, and +15% in Germany for   desferrioxamine vs 
deferasirox. Incremental improvements in persistence were +9 months in the UK and +8 months 
in Germany for alendronate once weekly vs once daily, +4 months in the UK and +3 months 
in Germany for extended-release vs immediate-release methylphenidate, and +2 months in 
Germany for deferasirox vs desferrioxamine.
Conclusion: The new formulations that we evaluated were associated with better compliance 
and persistence compared with older formulations. Despite the fact that some sources of bias 
could not be excluded, it is likely that these improvements can be attributed to the lower treatment 
burdens of the galenic formulations of the drugs considered. Further investigation is required to 
confirm these findings and to determine whether new galenic formulations can improve health 
outcomes in routine clinical practice.
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Introduction
Advances in pharmacotherapy are typically perceived as being related to the availability 
of new molecular entities or compounds. However, there has been a gradual change 
in the way many stakeholders think about innovation in light of several scientific 
publications,1,2 official documents,3,4 and the use of value-based pricing in an   increasing 
number of countries.5 A more holistic view of innovation places less emphasis on 
developmental considerations, such as creation of new molecules (with whatever 
degree of structural novelty) and more emphasis on individual patients and society 
as a whole, with improvements in health outcomes driving research into, and rewards ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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for, pharmaceutical innovation. Such a system assesses the 
value of new molecules and galenic enhancements using the 
same terms of reference (ie, health outcomes).
While there is abundant clinical research comparing 
new molecules with placebo or an active comparator, there 
has traditionally been a lack of head-to-head comparisons 
between different galenic formulations of the same active 
molecule in “real-world” clinical practice. Therefore, there 
is little information available to describe the effects of new 
formulations on compliance and persistence despite the 
important effects of medication-taking behavior on   clinical 
outcomes. Noncompliance with treatment and medical 
advice may cause accelerated disease, increased outpatient 
visits, more admissions to hospital, and impaired ability to 
predict the effectiveness of treatment.6 In addition, increased 
morbidity and mortality due to noncompliance may increase 
health care costs.7–10
Compliance is affected by numerous factors, which can be 
broadly classified as being related to the patient, society, and 
the treatment.11 Treatment-related factors include the mode of 
delivery, frequency of administration, and adverse effects.11 
Reducing the burden of treatment, by simplifying treatment 
regimens for example, may have the potential to enhance 
compliance11 and ultimately the outcomes of treatment.12–14 
New formulations often have less complex regimens (eg, less 
frequent dosing) or more convenient routes of administration 
(eg, oral instead of intravenous infusion). However, while 
several studies have shown (for example) that once-daily 
treatments are associated with higher rates of compliance 
than more complex regimens,15–18 few studies have directly 
compared persistence and compliance between galenically 
different molecular analogs or near-analogs.
Materials and methods
Objective
The objective of the study was to determine whether newer 
galenic formulations of drugs with lower treatment burdens 
are associated with better patient compliance and persistence 
compared with older more burdensome modalities. To 
explore the potential for new galenic formulations to improve 
compliance and persistence, we retrospectively reviewed data 
from the IMS Disease Analyzer database.
Database content and selection  
of analogs
The Intercontinental Medical Statistics (IMS) Disease 
Analyzer database includes data collected directly from 
computers in physicians’ practices in   Germany and the UK 
and provides daily routine information on patients’ diseases 
and therapies, allowing tracking of   prescription   history. Each 
practice transmits patient data to IMS on a monthly basis. 
The database includes only   anonymized data in compliance 
with applicable data protection legislation. The IMS Dis-
ease Analyzer database was reviewed to   identify products 
that had undergone a formulation change with the potential 
to provide a major benefit for patients, such as improved 
convenience or reduced treatment burden. Products were 
considered for inclusion in the study if they were   indicated 
for a condition that was associated with a high disease bur-
den and required long-term treatment, and if their entries 
in the database included data on the timing and nature of 
prescriptions. Based on these criteria, three pairs of products 
were identified, ie, alendronate (Fosamax®) once daily and 
once weekly, methylphenidate immediate-release (Ritalin®) 
and extended-release (Concerta®), and a pair of drugs with 
similar indications but important differences in convenience 
and dosing instructions (desferrioxamine [Desferal®] and 
deferasirox [Exjade®]).
Alendronate once daily is indicated for prevention of frac-
tures in men and postmenopausal women with osteoporosis, 
for treatment of glucocorticoid-induced osteoporosis, and 
to prevent bone loss in postmenopausal women at risk 
of osteoporosis.19 In Germany, alendronate once daily 
is indicated to reduce the risk of new vertebral and hip 
fractures in postmenopausal women without pre-existing 
vertebral fractures and for the treatment and prevention of 
glucocorticoid-induced osteoporosis in men and women not 
receiving estrogens, and is formulated as a 10 mg oral tablet.20 
Alendronate weekly is indicated for prevention of fractures 
in postmenopausal women with osteoporosis in the UK and 
Germany and is formulated as a 70 mg oral tablet.21,22 Both 
alendronate products have restrictive dosing instructions. 
Tablets must be taken at least 30 minutes before the first food, 
beverage, or medicinal product of the day with plain water 
only. Patients must take the tablets with a full glass of water 
(at least 200 mL) and must not lie down until after their first 
food of the day. The tablet must be swallowed whole and 
must not be crushed or chewed.
Immediate-release and extended-release methylphenidate 
are both indicated for management of attention-deficit 
hyperactivity disorder (ADHD) in children aged 6 years of 
age and older.23–25 Immediate-release methylphenidate is 
formulated as a 10 mg tablet and requires careful dose titration, 
beginning once or twice daily (eg, at breakfast and lunch) ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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with the dose and frequency increased up to a maximum of 
60 mg/day if required.25 A small evening dose may be required 
if the effects wear off. Extended-release methylphenidate is 
formulated as an 18 mg, 27 mg, or 36 mg capsule-shaped tablet 
and must be swallowed whole with the aid of liquids, and must 
not be chewed, divided, or crushed. It may be administered with 
or without food and is taken once daily in the morning.23,24 
Doses may be adjusted in 18 mg increments starting with the 
lowest dose up to a maximum of 54 mg/day.
Desferrioxamine is formulated as a sterile, lyophilized 
powder for reconstitution in a vial containing 500 mg 
or 2 g of drug,26 whereas deferasirox is formulated as a 
dispersible 125 mg, 250 mg, or 500 mg tablet.27 In the 
UK, desferrioxamine is indicated for treatment of chronic 
iron overload, primary and secondary hemochromatosis, 
acute iron poisoning, and aluminum overload, and requires 
reconstitution before intravenous infusion, intramuscular 
injection, or subcutaneous infusion (the route of delivery 
depends on the condition being treated, with an average 
daily dose of 20–60 mg/kg/day adjusted based on initial 
monitoring of urinary ferritin).26 Deferasirox is indicated 
for chronic iron overload due to frequent blood transfusions 
in patients with beta thalassemia major aged 6 years and 
older and for treatment of chronic iron overload due to blood 
transfusions when desferrioxamine therapy is contraindicated 
or inadequate. It is administered once daily on an empty 
stomach at least 30 minutes before food, preferably at the 
same time each day, usually at an initial dose of 20 mg/kg with 
adjustments in 5–10 mg/kg increments based on monitoring 
of serum ferritin.27 In Germany, deferasirox is indicated for 
the management of chronic iron overload due to frequent 
transfusions in patients with beta thalassemia major 
over 6 years of age and for the management of chronic 
transfusional iron overload.28 The tablets are dispersed by 
stirring in a glass of water or orange or apple juice. Any 
residue remaining in the glass must be resuspended in a small 
volume of water or juice and swallowed.
Data retrieval and analysis
Data were retrieved from the IMS Disease Analyzer database. 
Records were available for patients treated in the UK and 
Germany. Analyses of alendronate and methylphenidate 
included patients from the UK and Germany. Analysis of 
desferrioxamine and deferasirox was restricted to patients 
from Germany, because complete data were not available 
for patients receiving these products in the UK. All patients 
receiving any of the products were included in the analyses.
Patients included in the analysis had to be initiated on 
the formulation of interest and not received any previous 
prescription for the same combination of substance and 
formulation. Patients had to have treatment initiated between 
January 2003 and December 2007 in order to provide for a 
follow-up period of at least 2 years at the time of analysis 
(December 2009). For each patient included in the analysis, 
information was retrieved from the database to identify the 
substance, formulation, and dose. Dates of prescriptions, 
quantity of medication, dosage, and prescription duration 
were used to calculate compliance and persistence.
Compliance is generally defined as the act of following 
the treatment recommendations made by the prescriber in 
terms of dose and frequency of medication.29 It is measured 
over a period of time and is expressed as a percentage. In our 
study, compliance was calculated as the sum of the durations 
of prescribed treatments for an individual patient over a 
1-year period. For the chronic conditions considered in our 
analyses, it was assumed that patients required treatment 
continuously throughout the study period and that gaps in 
the prescribing history reflected noncompliance. The 1-year 
period was selected to capture sufficient prescription data 
without biasing the results by including patients who had 
stopped using the drug (as would have been the case if longer 
time periods had been used).
Persistence is generally defined as the duration of treatment 
from initiation until discontinuation and can be reported as a 
continuous variable (number of days for which the medication 
was available) or a dichotomous variable (persistent or 
nonpersistent) at the end of the observation period.29 In our 
study, treatment periods evaluated for persistence were 
calculated as the time between the first and last prescription 
using the quantity prescribed and dosage instruction issued 
by the doctor. A 2-year time period was used for analysis of 
persistence to account for patients using the drugs for periods 
of time greater than the 1-year period used for analysis of 
compliance. However, due to the recent introduction of 
deferasirox at the time of analysis, data were not available for 
2 years and persistence was therefore calculated over 1 year 
for both deferasirox and desferrioxamine. As per definition, 
gaps in prescribed treatment were not taken into account 
for the analysis of persistence. Patients were considered 
nonpersistent if they stopped taking the medication for any 
reason, including switching to another medication or no longer 
requiring treatment. A patient was defined as having stopped 
medication if he or she had no current prescription for that 
medication at the time of analysis.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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Results
For alendronate once daily and weekly, data on persistence 
and compliance were retrieved for 595 and 13,468 patients, 
respectively, in the UK, and 554 and 8941, respectively, 
in Germany. For immediate-release and extended-release 
methylphenidate, data were retrieved for 449 and 590 patients, 
respectively, in the UK, and 594 and 483, respectively, 
in Germany. For desferrioxamine and deferasirox, data 
were retrieved for 518 and 2229 patients, respectively, in 
Germany.
Compliance
For all three pairs of products, compliance was higher 
with the newer formulations than with the original 
agents (Table 1). Absolute incremental improvements in 
compliance over 1 year were +30% in the UK and +26% in 
Germany for alendronate once weekly vs once daily, +14% 
in the UK and +19% in Germany for extended-release 
vs immediate-release methylphenidate, and +15% in Germany 
for desferrioxamine vs deferasirox. Among patients receiving 
alendronate once daily, 33% in the UK and 40% in Germany 
took their medication for 0%–10% of the time during the 
first year, compared with 10% and 17%, respectively, for 
alendronate weekly. Higher percentages of patients receiving 
alendronate weekly (52% in the UK and 33% in Germany) 
took their medication at least 90% of the time over 1 year, 
compared with those receiving alendronate once daily 
(21% in the UK and 14% in Germany). Similarly, 15% of 
immediate-release methylphenidate recipients in the UK and 
39% in Germany took their medication for 0%–10% of the 
time, compared with 9% and 16%, respectively, for extended-
release methylphenidate. Patients receiving extended-release 
methylphenidate were more likely to take their medication 
at least 90% of the time over 1 year (46% in the UK and 
17% in Germany), compared with patients   receiving 
immediate-  release methylphenidate (28% in the UK and 5% 
in Germany). Among patients receiving   desferrioxamine in 
Germany, 47% took their medication for 0%–10% of the time 
during the first year, compared with 26% for deferasirox. 
Similar percentages of German patients receiving deferasirox 
(16%) and desferrioxamine (14%) took their medication at 
least 90% of the time over 1 year.
Persistence
Persistence was higher for all three newer formulations, 
compared with the respective older formulations (Table 2). 
Incremental improvements in persistence over 2 years 
were +9 months in the UK and +8 months in Germany 
for alendronate once weekly vs once daily, +4 months in 
the UK and +3 months in Germany for extended-release 
vs   immediate-release methylphenidate, and +2 months in 
  Germany for deferasirox vs desferrioxamine. Among patients 
receiving alendronate weekly, 63% in the UK and 42% in 
Germany took their medication for at least 2 years, compared 
with 22% and 12%, respectively, for alendronate once daily. 
Patients receiving alendronate weekly were less likely to stop 
taking their medication during the first 2 months (12% in the 
UK and 17% in Germany), compared with alendronate once 
daily (41% in the UK and 54% in Germany).   Similarly, 69% 
of extended-release methylphenidate recipients in the UK and 
41% in Germany took their medication for at least 2 years, 
compared with 42% and 32%, respectively, for immediate-
release methylphenidate. The percentage of patients who 
stopped taking their medication during months 1 or 2 was 
Table 1 Mean compliance over 1 year
Compliance (%) Incremental  
compliance (%) Older  
formulation
Newer  
formulation
Alendronatea
  UK 40 70 +30
  germany 29 55 +26
Methylphenidateb
  UK 54 68 +14
  germany 27 46 +19
Desferrioxamine/ 
deferasiroxc
  germany 31 46 +15
Notes: aAlendronate once daily (older formulation) vs alendronate weekly (newer 
formulation); bimmediate-release methylphenidate (older formulation) vs extended-
release methylphenidate (newer formulation); cdesferrioxamine (older formulation) 
vs deferasirox (newer formulation).
Table 2 Mean persistence over 2 years
Persistence (months) Incremental   
compliance  
(months)
Older 
formulation
Newer 
formulation
Alendronatea
  UK 9 18 +9
  germany 6 14 +8
Methylphenidateb
  UK 15 19 +4
  germany 11 14 +3
Desferrioxamine/
deferasiroxc
  germany 5 7 +2
Notes: aAlendronate once daily (older formulation) vs alendronate weekly (newer 
formulation); bimmediate-release methylphenidate (older formulation) vs extended-
release methylphenidate (newer formulation); cdesferrioxamine (older formulation) 
vs deferasirox (newer formulation).ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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lower with extended-release methylphenidate (9% in the 
UK and 25% in Germany) than with immediate-release 
methylphenidate (18% in the UK and 37% in Germany). 
Among patients receiving deferasirox in Germany, 31% 
took their medication for over 2 years, compared with 25% 
for desferrioxamine. In Germany, fewer patients stopped 
taking deferasirox (29%) during months 1 and 2, compared 
with desferrioxamine (38%).
Discussion
Our analyses indicate that, for the three selected pairs of 
  products, newer agents with improved galenic formulations 
were associated with higher rates of compliance and   persistence 
than older formulations. Newer products   (alendronate weekly, 
extended-release methylphenidate, and deferasirox) were 
associated with incremental improvements in 1-year compli-
ance of between 14% and 30% vs older products (alendronate 
once daily, immediate-release methylphenidate, and desfer-
rioxamine). The newer products were also associated with 
higher mean persistence (increments of 2–9 months) com-
pared with the older products. The difference in compliance 
and persistence between the methylphenidate formulations 
occurred despite the fact that placebo-controlled studies have 
indicated that some adverse events (especially insomnia) may 
be more frequent with longer-acting products.30 Therefore, our 
findings indicate that the greater convenience of extended-
  release methylphenidate may outweigh possible disadvan-
tages related to a higher incidence of adverse effects.
The differences in compliance and persistence between 
deferasirox and desferrioxamine were smaller than the 
differences between weekly and once-daily alendronate 
or between extended-release and immediate-release 
methylphenidate. The smaller difference in persistence may 
have been related to the shorter assessment period used in 
patients receiving deferasirox and desferrioxamine (1 year) 
compared with the other pairs of products (2 years). The 
smaller difference between deferasirox and desferrioxamine, 
compared with the differences between weekly and once-
daily alendronate, may also have been related to the fact that 
many patients who require deferasirox or desferrioxamine 
for beta thalassemia are children who will be assisted by 
their parents when taking the medication. This assistance 
may have increased rates of compliance and persistence. 
However, many patients receiving methylphenidate are 
young children, so it is unlikely that differences in parental 
assistance could explain the difference between deferasirox 
and desferrioxamine, compared with the difference between 
immediate-release and extended-release methylphenidate.
The higher compliance and persistence associated with 
the newer formulations might be related to a lower treatment 
burden compared with the older products. For example, 
alendronate has restrictive dosing instructions, and the 
difference in dosing frequency between formulations might 
result in a lower burden for patients receiving the weekly 
formulation, compared with daily dosing. Similarly, extend-
ed-release methylphenidate is given once daily at breakfast 
whereas immediate-release methylphenidate is given up to 
three times a day, requiring children to take the tablets dur-
ing their school day. Deferasirox is also easier to administer 
(dispersed in water or fruit juice) than desferrioxamine 
(reconstituted and infused using a pump for five nights per 
week).
While the aforementioned causal attribution appears 
plausible, several limitations of the study should be noted. 
Our findings indicate that the newer treatments were 
associated with higher compliance and persistence than 
the older treatments. However, the possibility that these 
findings were due to differences between the populations 
being prescribed each product, rather than to the products 
themselves, cannot be ruled out. No data are available 
to determine whether there were meaningful differences 
between the patient populations. Because this was a 
retrospective study, the patients were not randomized to the 
various treatment groups and there may have been differences 
between the populations receiving the newer vs the older 
formulations. For example, physicians may have been more 
inclined to prescribe newer formulations to certain patients 
(eg, those with more severe disease) than to others (selection 
bias). Having said that, it appears unclear in which direction 
(overestimation or underestimation) this bias would work. 
Further, our analysis could not adjust for the influence of 
industry-driven promotion and disease education, which may 
also affect the uptake of newer treatments.
Although the IMS database provides a representative 
sample of German and UK patient populations, it should 
also be noted that our findings may not be applicable 
to other countries. It is also important to note that our 
assessments of compliance and persistence were based on 
the number of prescriptions and did not take account of 
whether patients actually filled the prescription or took the 
medication. Therefore, our analyses may have overestimated 
both compliance and persistence. Assuming that both arms 
of each pair-wise comparison were affected equally by a 
potential overestimation, this would not have affected the 
incremental analysis. However, as mentioned before, any 
potential selection effects are unclear or unknown.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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While our study did not directly assess the burden 
associated with each treatment, several other studies have 
indicated that newer formulations are associated with 
improved patient satisfaction and quality of life, compared 
with older formulations. For example, patients receiving 
deferasirox have been shown to have improved satisfaction 
and quality of life, lower levels of anxiety and depression, and 
higher compliance, compared with previous treatments.31–38 In 
addition, a study of patients receiving iron chelating therapy 
(injected or oral) showed that four variables were significant 
predictors of never thinking about stopping treatment, ie, age, 
perceived effectiveness of therapy, burden of therapy, and low 
incidence of adverse effects.39 Studies have also shown that 
weekly or monthly dosing with bisphosphonates (alendronate 
or ibandronate) is preferred by many patients, compared with 
daily dosing,40–42 and that weekly alendronate is associated 
with higher compliance than daily bisphosphonates.43
If reformulation of a product results in improved 
compliance and persistence, it would be reasonable to 
hypothesize that there might be an associated improvement in 
efficacy. A small number of studies have compared extended-
release and immediate-release methylphenidate, including 
two that showed that switching from immediate-release 
to extended-release methylphenidate improved symptom 
control in children and adolescents with ADHD.44,45 There 
was also an improvement in compliance after the switch in 
one of these studies;44 no data on compliance were provided 
in the published results from the other study.45 In addition, 
a study of children with ADHD who were poorly compliant 
with immediate-release methylphenidate showed that, after 
switching to extended-release methylphenidate, 72% of 
children had good compliance.46 This improvement was 
accompanied by improvements in symptom control. However, 
a randomized study in children with ADHD showed that 
the two methylphenidate formulations had similar efficacy, 
despite a slightly higher completion rate with extended-release 
methylphenidate (81%) than with the immediate-release 
formulation (75%).47 In contrast, another study in children 
with ADHD showed that extended-release methylphenidate 
was more effective than immediate-release methylphenidate, 
but there was no difference in discontinuation rates during 
the study.48 Overall, these studies indicate that switching 
from immediate-release to extended-release methylphenidate 
may improve compliance, but it remains unclear whether 
increases in compliance or persistence translate into improved 
efficacy in routine clinical practice.
Several studies have compared deferasirox and 
  desferrioxamine. A study in patients with transfusional iron 
overload due to sickle cell disease showed that deferasirox 
and desferrioxamine resulted in similar reductions in liver 
iron concentration.49 Discontinuation rates were similar 
between deferasirox (11.4%) and desferrioxamine (11.1%).49 
Efficacy (reduction in liver iron concentration) was also simi-
lar between deferasirox and desferrioxamine in a study of 
patients with transfusional iron overload due to thalassemia, 
although no information on discontinuation rates was 
provided in the publication from that study.50
Comparisons of alendronate weekly (70 mg or 35 mg 
once weekly) and once daily (10 mg or 5 mg) have shown 
that the two products are therapeutically equivalent and have 
similar safety and tolerability.51–53 However, there have been 
no studies comparing the efficacy of the two formulations 
in a “real-world” setting.
Conclusion
Our analysis indicates that the reduced treatment burdens 
attributed to new galenic formulations which we evaluated 
against their older counterparts are associated with better 
compliance and persistence. Further investigation, with 
different study designs and the inclusion of additional control 
variables, is required to confirm these findings and to evaluate 
the extent to which new galenic formulations can ultimately 
improve health outcomes in routine clinical practice.
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